In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litig., No. 18-md-2819 (E.D.N.Y.)


In the Restasis case, Faruqi & Faruqi represents a proposed class of direct purchasers of Restasis. The direct purchasers alleged that the drug’s manufacturer, Allergan, Inc., delayed entry of a generic version of Restasis by procuring patents by fraud, listing those fraudulently acquired patents in the Orange Book, filing serial sham petitions with the FDA, and transferring ownership of the fraudulently acquired patents to the Saint Regis Mohawk Tribe and asserting the Tribe’s sovereign immunity. A settlement of $51 million was reached with Allergan in February 2020 and was finally approved by the court on October 7, 2020.

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.

Details

Filed on 12/11/2017

Office

1617 JFK Boulevard, Suite 1550

19103 Philadelphia, Pennsylvania

Phone (215) 277-5770

Fax (215) 277-5771

Counsel

Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771

Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885

Georgia

3975 Roswell Rd Suite A
Atlanta, Georgia 30342
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania